DRTS

RadTech

Alpha Tau Medical Ltd.

15.04
▲ 0.50 (+3.44%)
Needs attentionEstimated cash runway of ~3-4 months ($12.2M cash vs. -$42.3M TTM EBITDA) is far below the 24-month threshold for a pre-revenue name ahead of a value-inflection readout.
Price · volume · estimated price

Chart

15.04
Sep 28, 2026 · Vol 397.4K
15.04
Thesis

At a glance

No thesis note yet.

Market signals · technical

Price & volume signals

Technical signals from price history, for your own read of market timing. These never affect the Estimated Price — they sit apart from the valuation by design.

Trend
Above averages
price vs SMAs
RSI (14)
52
neutral
Volume trend
falling
-29% (10 vs 10)
SMA 20
14.73
SMA 50
n/a
SMA 200
n/a

· Only 47 bars — the 50/200-day averages need more history.

Trailing twelve months · from XBRL

Fundamentals

as of Dec 31, 2025
Revenue
$0
Gross margin
—
EBITDA
−$42.3M
EBITDA margin
—
Net income
−$42.6M
EPS
-0.48
Cash
$12.2M
Total debt
$0
Net debt
−$12.2M
Net leverage
—
Book value
$77.1M
Backlog
—
Position

Position

No open position. Record a trade on the Portfolio tab and it flows into this card.

Company status · synthesized

Status

Full history →Sep 28, 2026
What happened

No multi-year arc can be constructed: there are zero fiscal years of revenue on file and only a single fiscal year of financials exists, so revenue CAGR and growth volatility are not computable. The only available snapshot is for 2025-12-31, showing revenue of 0, EBITDA of -42,288,000, and net income of -42,627,000; no filing events are available to tie these to a trajectory.

Where it stands

As of 2025-12-31, the company has no revenue, EBITDA of -42,288,000, net income of -42,627,000, cash of 12,202,000, zero total debt, and equity of 77,099,000. No active flags are present, so there are no computed warning or positive indicators to incorporate.

Active flags
  • Estimated cash runway of ~3-4 months ($12.2M cash vs. -$42.3M TTM EBITDA) is far below the 24-month threshold for a pre-revenue name ahead of a value-inflection readout.

    critical · rule-runway

What's ahead

No qualitative outlook data available for this market yet — this market's filings are not parsed for management outlook, strategic priorities, or capex plans. The forward view rests on the valuation assumptions and any pending recalibration only.

Synthesized by deepseek-v4-flash over already-extracted filing facts, trajectory stats, and computed flags. Interpretation only — it moves no valuation number.

EDGAR · diffed daily

Filings & extraction

No filings ingested yet.

Review queue · nothing auto-saves

News & signals

0 queued

No signals for this name.

Illustrative data where noted. Not investment advice.